Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity

v3.19.3
Stockholders' Equity
12 Months Ended
Jul. 31, 2019
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]

Note 11 - Stockholders’ equity


Controlled Equity Offering


The Company has a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0 million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million.


On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.2 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017.


For the years ended July 31, 2019, 2018, and 2017 the Company did not sell any shares of common stock under the Sales Agreement.


Treasury stock


During fiscal year 2018, certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 previously acquired shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. All of the treasury shares were subsequently reissued in the share-based 401(k) employer match made during fiscal year ended July 31, 2018.


Common stock


In fiscal 2019, the Company issued 315,472 shares of common stock for its employees’ 401(k) matching contribution obligation. The Company recorded an expense of $832 for the match representing the fair value of the shares at the date of issuance.


In fiscal 2018, the Company used 106,911 shares of treasury stock and issued 37,580 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $782 for the match, representing the fair value of the shares at the date of issuance.


In fiscal 2017, the Company issued 91,541 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $724 for the match representing the fair value of the shares at the date of issuance.


Incentive stock plans


In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan to increase the number of shares available for issuance by 2,000,000 bringing the total number of shares available for award under the 2011 Plan to 5,000,000. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired. As of July 31, 2019, there were approximately 1,223,000 shares available for grant under the 2011 Plan.


The Company estimates the fair value of each stock option award on the measurement date using a Black-Scholes option pricing model. The fair value of awards is amortized to expense on a straight line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed.


Options granted pursuant to the plans may be either incentive stock options or non-statutory options The 2011 Plan provides for the issuance of stock options, restricted stock and restricted stock unit awards which generally vest over a two to four year period. A summary of the activity pursuant to the Company’s stock option plans for the years ended July 31, 2019, 2018, and 2017 is as follows:


    2019     2018     2017  
    Options     Weighted -
Average
Exercise
Price
    Options     Weighted -
Average
Exercise
Price
    Options     Weighted -
Average
Exercise
Price
 
Outstanding at beginning of year     1,882,116     $ 4.96       2,132,995     $ 4.26       1,813,875     $ 3.43  
New Grants     715,321     $ 2.81       415,580     $ 5.57       493,996     $ 7.07  
Exercised     (238,230 )   $ 2.69       (635,624 )   $ 2.98       (141,876 )   $ 3.19  
Expired     (8,167 )   $ 6.55       (30,835 )   $ 5.97       (33,000 )   $ 5.29  
Outstanding at end of year     2,351,040     $ 4.53       1,882,116     $ 4.99       2,132,995     $ 4.26  
Exercisable at end of year     1,342,564     $ 5.16       1,149,489     $ 4.28       1,388,475     $ 3.27  
Weighted average fair value of options granted during year           $ 1.07             $ 1.91             $ 2.45  

The intrinsic value of stock option awards that vested during the fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excess of the exercise price multiplied by the number of options that vested. Total intrinsic value of options that vested and were exercisable during the fiscal years ended July 31, 2019, 2018, and 2017 was $159, $743 and $10,530, respectively. The intrinsic value of options outstanding at July 31, 2019, 2018, and 2017 was $955, $1,723 and $14,510, respectively. The intrinsic value of the options exercised in fiscal 2019, 2018 and 2017 was $117, $6,014 and $1,388, respectively.


During the fiscal year ended July 31, 2019 certain directors and officers of the Company exercised 203,511 stock options in non-cash transactions. The officers and directors received 23,376 net shares of common stock. The Company did not receive any proceeds from this exercise. The net shares issued represent the difference between the fair market value of the options on the date of exercise less the strike price cost to exercise the options.


Listed below are the assumptions used to fair value options granted during fiscal years 2019, 2018 and 2017:


Grant
Year
    Options
Granted
    Exercise
Price Range
    Term
(years)
    Vesting
Period

(years)
    FMV of
options
Granted/Per

Share
    Expected
Life
(years)
  Expected
Volatility %
  Interest
Rate %
  Vested
Shares at
7/31/2019
 
                                                   
2019     715,321     $2.80 - $3.21     5     2 - 3     $1.06 – $1.23     3.25 - 3.5   48.06 - 50.56   2.47- 2.96    
                                                   
2018     415,580     $4.42 - $8.36     5     2 - 3     $1.53 - $2.76     3.25 - 3.5   42.59 - 46.14   2.07- 2.79   166,860  
                                                   
2017     493,996     $7.07     5     2 - 3     $2.40 - $2.48     3.25 - 3.5   45.85 - 46.28   1.48- 1.54   394,296  

The following table summarizes information for stock options outstanding at July 31, 2019:


Range of Exercise prices Range of Exercise prices     Shares    

Weighted-Average

Remaining Contractual

Life in Years

 

Weighted-Average

Exercise Price

$2.80 $4.35     1,266,592       1.58   $ 3.25
$4.42 $7.07     968,868       1.10   $ 5.75
$8.25 $8.36     115,580       0.17   $ 8.36
      2,351,040                  

Restricted Stock Awards


During fiscal 2017, the compensation committee of the Company’s board of directors approved grants of restricted stock and restricted stock unit awards (the “Awards”) to certain officers and certain employees under the 2011 Plan. The Awards vest upon the recipient’s continued employment service rateably over four years. Share-based compensation expense is based on the fair value of the award as measured on the grant date and is recorded over the vesting period on a straight-line basis. The Awards will be forfeited if the recipient ceases to be employed by the Company, as defined in the Plans’ terms. The Awards settle in shares of the Company’s common stock on a one-for-one basis.


The following table summarizes the activity pursuant to restricted stock awards for the years ended July 31,


    2019     2018     2017  
    Awards     Weighted -
Average
Grant Date
Fair Value
    Awards     Weighted -
Average
Grant Date
Fair Value
    Awards     Weighted -
Average
Grant Date
Fair Value
 
Outstanding at beginning of year     2,613     $ 1.74       7,436     $ 4.45       8,501     $ 4.13  
Awarded         $           $       4,250     $ 6.95  
Vested     (986 )   $ (6.71 )     (2,874 )   $ (5.20 )     (5,140 )   $ (4.10 )
Forfeited         $       (1,949 )   $ (5.18 )     (175 )   $ (2.14 )
Outstanding (non-vested) at end of year     1,627     $ 5.14       2,613     $ 1.74       7,436     $ 4.45  
Weighted average market value of awards granted during year           $             $             $ 6.95  

The fair value of the awards that vested during the years ended July 31, 2019, 2018 and 2017 was $4, $24 and $44, respectively.


Performance Stock Units


To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company granted long-term incentive awards in the form of time based stock options and performance-based restricted stock units (“Performance Stock Units” or “PSUs”). The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group.


During fiscal year 2019 and 2018, the Company awarded PSUs to its executive officers which provide for the grant of shares of our common stock at the end of three–year periods based on the achievement of average revenue growth and adjusted EBITDA growth over the respective periods. As of July 31, 2019, the Company did not accrue any compensation expense for these PSU’s as the achievement of the growth goals is currently not probable.


The following table summarizes PSU’s granted:


 

Period
Ending

   

Total
Grant

   

Fair Market Value
At Grant Date

 
    7/31/2019       80,500     $         225  
                     
    7/31/2018       32,000     $         141